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Glioblastoma multiforme (GBM) is the most common 
malignant brain tumor in adults. The current standard of care 
includes surgery followed by radiotherapy (RT) and 
chemotherapy with temozolomide (TMZ). Treatment often 
fails due to the radiation and TMZ resistance of a small 
percentage of cells with stem cell-like behavior (CSC). The 
Notch signaling pathway is expressed and active in human 
glioblastoma and Notch inhibitors attenuate tumor growth in 
vivo in xenograft models. Here I will discuss the results of 
studies investigating combination treatments of RT 
Temozolomide and NOTCH inhibitors in an orthotopic model 
of Glioblastoma. Small Animal image guided preciscion 
Radiotherapy (SmART) treatment planning and delivery was 
used to achieve highly accurate dose prescriptions and 
treatment monitoring. Studies will be presented that 
investigate the role for NOTCH signaling in treatment 
response in different 2D and 3D culture systems. 
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Figure Legend: SmART image-guided treatment plan for 
orthotopic GBM model. PTV (red), normal brain (blue) and 
parallel irradiation beams (green) 
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Stroma mediated wound healing signals induced by 
radiotherapy have been well characterized in normal tissue 
response and fibrosis. They are complex and involve the 
crosstalk between the various cellular type of the tissue 
including fibroblasts, endothelial, immune, epithelial cells as 
well as soluble paracrine factors including growth factors and 
proteases. In addition, recent studies suggest that these 
wound healing signals may share similarities with the ones 
produced by tumor’s microenvironment. Therefore, their 
modulation may impact both normal tissue and tumor 
response to radiation therapy. 
This lecture will illustrate the two important aspects of 
stroma mediated wound healing signals in normal tissue and 
tumour response to radiotherapy.   
In a recent study (1), we investigated the role of 
macrophages in radiation-induced lung fibrosis, profiled 
alveolar (AM) and interstitial macrophages (IM) and show that 
both macrophage subtypes are playing specific and opposite 
role in fibrogenesis. Acute depletion of AM post-irradiation 
was shown and associated with cytokine secretion. This acute 
depletion was followed by a repopulation mediated via the 
recruitment and proliferation of monocytes/macrophages 
from the bone marrow. Interestingly, the newly recruited 
Alveolar macropahages exhibited hybrid polarization 
(M1/M2), associated with the up-regulation of both Th1 and 
Th2 cytokines. At delayed times points post-irradiation, 
interstitial macrophages were M2 polarized and 
simultaneously, a down-regulation of Th1 cytokines and up-
regulation of Th2 cytokines was observed in irradiated lungs. 
The specific depletion of hybrid AM enhanced the severity of 
fibrosis whereas anti-fibrotic treatment based upon 
pravastatin administration decreased M2-IM levels.  We also 
found that M2-IM were able to activate fibroblast into 
myofibroblasts when co-cultured.   
In another study (2), we assessed the crosstalk between 
primary lung fibroblast and carcinoma cells (TC-1) in 
response to radiotherapy. We found that fibroblasts were not 
able to modulate intrinsic radiosensitivity of TC-1 but 
produce diffusible factors able to modify tumor cell fate. 
More specifically, RhoB deficient fibroblasts stimulated TC-1 
migration through MMPs production whereas WT fibroblasts 
produce TGF-.  In addition RhoB deficiency stimulated pro-
inflammatory signals (IL-6) that would impact on immune 
recruitment and favor antitumor immune response. In 
addition, co-irradiation of fibroblasts and TC-1 abrogated the 
pro-migratory phenotype by repression of TGF-β and MMP 
secretion. This last result suggests that conversely to, the 
current view; irradiated stroma would not enhance 
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carcinoma migration and could be manipulated to promote 
anti-tumor immune response. The role of macrophages in this 
system is currently investigated.  
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During the past decades, important progress has been made 
in the treatment of cancer. With early detection and more 
effective treatments, cancer has become a curable disease 
for many patients, while for others it could now be 
considered a chronic disease. As a consequence, the number 
of long-term cancer survivors is rapidly increasing, in 
particular among patients treated for Hodgkin’s lymphoma, 
testicular, prostate, colo-rectal, breast cancer or children’s 
leukemia. 
Most of these patients, however, face immediate (mostly 
transient) and long term (mostly irreversible) physical and 
mental side effects: hair loss, changes in body image, 
fatigue, depression, cognitive dysfunction, as well as 
increased risk of cardiovascular disease, bone loss, infertility 
and secondary malignancies. Cancer survivors are also 
confronted with socio-economical consequences of their 
disease, including too often exclusion from insurances, 
mortgages and loss of jobs. 
Most of the current knowledge regarding the long-term side 
effects of cancer and its treatment is based on registry data 
that is missing important treatment details. Clinical trial 
databases on the other hand include treatment and outcome 
data, but often fail to produce very long-term follow-up of 
outcome and late effects because of the high costs of 
conducting such long-term follow-up. 
The European Organisation for Research and Treatment of 
Cancer (EORTC) Survivorship Task Force aims to use and, if 
needed, to complete the impressive EORTC databases 
accumulated over 50 years of conducting cancer clinical 
trials. The goal is to document and analyse how long-term 
outcomes and side effects are associated with cancer 
treatment. With experience in updates of lymphoma and 
leukemia trials, early breast cancer trials are now being 
assessed as well. These studies provide large patient numbers 
(over 6000 patients for the lymphoma studies and over 
10,000 patients for the early breast cancer cohort). For the 
lymphoma trials, the first results on cardiovascular disease 
and secondary malignancies (incidence and mortality) have 
recently been published. The effects of the different 
treatment components on these endpoints have been 
quantified. Additional information will be gathered through a 
number of questionnaires sent to survivors, asking them 
about the impact of cancer diagnosis and treatment on 
relationships (social situation, parenthood), education, work 
and insurance, fatigue, emotional well-being and quality of 
life. To estimate the relative risks compared to the general 
population, a linkage with data of registries from several 
geographic areas is needed. Establishing such a network will 
enable us to quantify the impact of cancer treatment on late 
side effects in absolute terms. 
The information that the EORTC will gather through this 
series of projects is expected to help and guide future 
patients in trading off treatment efficacy and late side 
effects, seen as important costs in surviving cancer. 
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Radiotherapy (RT) planning and delivery for cancer 
management has substantially evolved over the last three 
decades with lately the introduction of intensity modulated 
RT, image-guided RT and stereotactic ablative RT to name a 
few techniques. The evaluation of these ehigh precision 
delivery techniques in routine care and in clinical trials alike 
requires optimal RT quality (RTQA) assurance programs which 
aim at defining the range of acceptable variations and 
importantly developing mechanisms of action for correction 
and prevention of potential variations[1, 2]. RTQA outside a 
clinical trial is defined by all processes that ensure 
consistency of the dose prescription and the safe delivery of 
that prescription with regard to dose to the target and 
critical structures, minimization of the exposure of the RT 
personnel, particularly so the radiation technologists[3]. In the 
framework of clinical trials assessing the efficacy of RT with 
or without a combined modality, RTQA is also necessary to 
avoid the corruption of the study-endpoint[4], as RT variations 
from study protocol decrease the therapeutic effectiveness 
and/or increase the likelihood of radiation-induced 
toxicities[5]. Prospective trials have shown that RTQA 
variations have a significant impact on the primary study 
end-point and could bias the analysis of the trial results[6]. 
Other specific consideration for RTQA in trials includes, but is 
not limited to, education of the accruing sites in RT-trial 
guidelines, promotion of consistency between centers and 
estimation of inter-patient and inter-institutional variations. 
Additionally, global cooperation is essential in the 
environment of common and rare cancers alike, in order to 
be able to create sufficiently large patient data sets within a 
reasonable recruitment period. This cooperation is not 
without issues and recently the need to have harmonized 
